检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:马红艳[1] 肖斌[2] 杨军[1] 顾峻菱 万沁[1] 徐勇[1]
机构地区:[1]泸州医学院附属医院内分泌科,646000 [2]泸州医学院生化教研室,646000 [3]重庆第五人民医院,400054
出 处:《实用医学杂志》2011年第2期192-194,共3页The Journal of Practical Medicine
基 金:国家自然科学基金资助项目(编号:30670980)
摘 要:目的:观察不同浓度高糖刺激后大鼠肾小球系膜细胞内Smad2/3和Smad7蛋白的表达,探讨糖尿病时肾脏Smad信号通路的改变。方法:将体外培养的大鼠肾系膜细胞分别设正常对照组(葡萄糖浓度5.6mmol/L)、20mmol/L高糖组、30mmol/L高糖组、甘露醇组。用细胞免疫荧光染色法及激光共聚焦显微镜检测各组细胞Smad2/3及Smad7蛋白的表达。结果:正常对照组系膜细胞Smad2/3蛋白表达较弱,Smad7蛋白表达较强。两高糖组Smad2/3表达较正常对照组强(P﹤0.05),呈浓度依赖性;Smad7表达较正常对照组弱(P﹤0.05),呈浓度依赖性。甘露醇组与正常对照组无明显差异(P﹥0.05)。结论:高糖可诱导肾系膜细胞Smad2/3蛋白表达增强,Smad7蛋白表达减弱。提示Smad信号通路参与了糖尿病肾病的发病机制。Objective To observe the expressions of Smad2/3 and Smad7 in glomerular mesangial cells (GMC) of rats under high glucose of different concentrations, and to investigate the change of Smad signal pathway under diabetic mellitus in rats. Methods GMC of rats cultured in votro were divided into control group (the concentration of glucose was 5.6 mmol/L),high glucose group (20 mmol/L and 30 mmol/L respectively),and mannitol group.The expressions of Smad2/3 and Smad7 in each group were measured by indirect immunofluorescence and laser scanning confocal microscope. Results The expression of Smad2/3 in control group was weak, whereas that of Smad7 was strong. The expressions of Smad2/3 in high glucose group were stronger than that in control group (P 〈 0.05), while those of Smad7 in high glucose group were weaker than that in control group (P 〈 0.05), both were in concentration-dependent manner. There were not significant differences of the expressions of Smad2/3 and Smad7 between mannitol group and control group. Conclusion High glucose can up-regulate the expression of Smad2/3 and down-regulate Smad7 in GMC of rats, indicating Smad signal pathway is involved in the pathogenesis of diabetic nephropathy.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.15